(Source: AbbVie Inc) - In Phase 3 clinical trials, VIEKIRAX + EXVIERA cured 95-100 percent of genotype 1 chronic hepatitis C patients, with less than 2 percent of patients experiencing virologic failure[1],[2] - All-oral, interferon-free regimen also approved for HCV/HIV-1 co-infection, patients on opioid substitution therapy and patients who have undergone a liver transplant[1],[2] - VIEKIRAX + EXVIERA are the first products to be approved as a combination treatment of three direct-acting antivirals with distinct mechanisms of action targeting hepatitis C at multiple steps in the viral lifecycle[1],[2] NORTH CHICAGO, Ill. , Jan. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced...
↧